Author:
El-Khoueiry Anthony,Lenz Heinz Josef
Reference66 articles.
1. Allen W, Johnston P. Have we made progress in pharmacogenomics? The implementation of molecular markers in colon cancer. Pharmacogenomics 6:1–9, 2005
2. Aschele C, Debernardis D, Tunesi G, et al. Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. Clin Cancer Res 6:4797–4802, 2000
3. Bertagnolli MM, Compton CC, Niedzwiecki D, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, 5-fluorouracil and leucovorin in stage III colon cancer. J Clin Oncol, ASCO Annual Meeting Proceedings. Part I. Vol. 24, No. 18S (June 20 Supplement), 10003, 2006
4. Bonner RF, Emmert-Buck M, Cole K, et al. Laser capture microdissection: molecular analysis of tissue. Science 278:1481–1483, 1997
5. Carlini L, Meropol N, Beve J, et al. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res 11:1226–1236, 2005